Madrigal director awarded RSUs and options

Madrigal Pharmaceuticals director Richard S. Levy received new equity awards.

Rhea-AI Filing Summary

Madrigal Pharmaceuticals director Richard S. Levy received new equity awards. He was granted 454 shares of common stock as restricted stock units and 766 stock options with an exercise price of $499.86 per share. Both awards vest in full on the earlier of June 17, 2027 or the company’s 2027 annual stockholder meeting, if he continues in service. After the grants, he directly owns 22,469 common shares.

Insider Trade Summary

Grant/Award: 1,220 shares

Grant/Award 2 txns

Insider Levy Richard S

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	766	$0.00	$0.00
Grant/Award	Common Stock	454	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 766 contracts (Direct); Common Stock — 22,469 shares (Direct)

Footnotes (2)

1. F1. Represents a grant of restricted stock units which vest on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date.
2. F2. The option vests as to 100% of underlying shares on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date.

Key Figures

RSU grant: 454 shares Option grant: 766 options Option exercise price: $499.86/share +2 more

5 metrics

RSU grant 454 shares Restricted stock units granted to director on June 17, 2026

Option grant 766 options Stock Option (Right to Buy) granted to director

Option exercise price $499.86/share Conversion or exercise price for 766 options

Common shares after grant 22,469 shares Total common stock held directly after RSU grant

Option expiration June 17, 2036 Expiration date of stock option grant

Key Terms

restricted stock units, Stock Option (Right to Buy), exercise price, vests as to 100% of underlying shares, +1 more

5 terms

restricted stock units financial

"Represents a grant of restricted stock units which vest on the earlier of"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "499.8600""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vests as to 100% of underlying shares financial

"The option vests as to 100% of underlying shares on the earlier of"

annual meeting of stockholders financial

"the date of the Issuer's annual meeting of stockholders to be held in 2027"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did MDGL director Richard S. Levy report?

Richard S. Levy reported receiving equity awards from Madrigal Pharmaceuticals. He was granted 454 restricted stock units and 766 stock options as compensation, with no open-market buying or selling involved in this Form 4 filing.

How many Madrigal Pharmaceuticals (MDGL) shares did Richard S. Levy receive?

Richard S. Levy received 454 shares of common stock in the form of restricted stock units. These units convert into shares as they vest, adding to his existing direct ownership in Madrigal Pharmaceuticals once vesting conditions are satisfied.

What are the terms of Richard S. Levy’s MDGL stock option grant?

Levy received 766 stock options with an exercise price of $499.86 per share. The options vest 100% on the earlier of June 17, 2027 or Madrigal’s 2027 annual stockholder meeting, and expire on June 17, 2036 if not exercised.

When do Richard S. Levy’s MDGL restricted stock units vest?

The 454 restricted stock units vest on the earlier of June 17, 2027 or the date of Madrigal Pharmaceuticals’ 2027 annual meeting of stockholders, provided Levy continues serving the company through the applicable vesting date.

How many MDGL shares does Richard S. Levy own after these grants?

Following the restricted stock unit grant, Levy directly owns 22,469 shares of Madrigal Pharmaceuticals common stock. This reported figure reflects his post-transaction direct holdings disclosed in the Form 4 filing for this grant event.

Were Richard S. Levy’s MDGL transactions open-market purchases or sales?

No, the transactions were compensation awards, not market trades. The Form 4 shows a grant of restricted stock units and stock options, both coded as acquisitions, with no reported open-market buying or selling activity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/18/2026 - 04:21 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Levy Richard S

(Last) (First) (Middle)

C/O MADRIGAL PHARMACEUTICALS, INC.

200 BARR HARBOR DRIVE, SUITE 400

(Street)

WEST CONSHOHOCKEN PENNSYLVANIA 19428

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MADRIGAL PHARMACEUTICALS, INC. [ MDGL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/17/2026		A(1)		454	A	$0	22,469	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$499.86	06/17/2026		A		766		(2)	06/17/2036	Common Stock	766	$0	766	D

Explanation of Responses:

1. Represents a grant of restricted stock units which vest on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date.

2. The option vests as to 100% of underlying shares on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date.

Remarks:

	/s/ Mardi Dier, as Attorney-in-Fact	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)